We Fight Diabetes!
Discovering Future Health.
We Fight Diabetes!
Discovering Future Health.
Over two-thirds of adults in this country are overweight, with a quarter suffering from obesity, which is massive overweight. The affected individuals are particularly at risk because often secondary diseases such as type 2 diabetes, cardiovascular diseases, or cancer occur. Thanks to excellent basic research, groundbreaking innovations against obesity as well as in the field of diabetes prevention and therapy are emerging at Helmholtz Munich.
Breakthrough solutions for better health.
Weight Loss Injection
Breakthrough solutions for obesity treatment and prevention of diabetes.
Gut hormone drugs are revolutionizing obesity treatment by not just promoting significant weight loss but also improving blood sugar, cholesterol and blood pressure, reducing diabetes and risk for heart diseases.
Helmholtz Munich CEO Prof. Matthias Tschöp played a pivotal role in this breakthrough, driven by his focus on the brain's role in appetite regulation. Decades of research led to key discoveries, resulting in groundbreaking medications like Tirzepatide.
Organ-on-Chip
Our vision: Personalized cell therapies for battling obesity or diabetes.
Scientists at Helmholtz Munich pioneer "organ-on-chip" technology, using chips to cultivate human stem cells and create organoids.
With a focus on type 1 diabetes, the scientists have created PancChip. By studying beta cell development within this artificial micro-pancreas, their goal is to grow patient-specific beta cells from stem cells for replacement therapy. This tackles the scarcity of donor cells and introduces innovative avenues for diabetes treatment.
Optoaucustic Imaging
Transforming diabetes detection with AI and Imaging Tech.
Researchers have developed a cutting-edge method using artificial intelligence and advanced imaging technology to measure changes in small blood vessels under the skin linked to diabetes.
This breakthrough could revolutionize diabetes monitoring and treatment.
Inceptor
Unlocking new pathways in diabetes treatment.
Helmholtz Munich scientists have made a significant breakthrough in diabetes research: the discovery of the insulin-inhibiting receptor, known as "inceptor."
This finding paves the way for innovative treatments for type 2 diabetes, as inceptor emerges as a promising therapeutic target.
Scientists are investigating drug classes that block inceptor, aiming to improve the health of beta cells. These efforts could help patients with type 2 diabetes and give new hope for enhanced treatments.
